In the treatment field of cardiac hypertrophy, current therapeutic approaches often focus on managing risk factors (e.g., hypertension) or blocking the action of neurohormonal factors However, drugs that modulate the function or expression of p130Cas or interfere with its downstream signaling pathways could offer novel treatments for cardiac myocyte hypertrophy [5]. The gene discussed is BCAR1; the disease is Hypertension.